KBC Group
PACB icon

KBC Group’s Pacific Biosciences PACB Stock Holding History

KBC Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,997
Closed -$37K – 1898
2024
Q1 		$37K Buy
9,997
+4,569
+84% +$26.8K ﹤0.01% 1697
2023
Q4 		$53K Hold
5,428
– – ﹤0.01% 1484
2023
Q3 		$45K Buy
+5,428
New +$62K ﹤0.01% 1536

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KBC Group's PACB Position: Q2 2024 in Review

KBC Group sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 9,997 shares — an estimated $37K sold.

KBC Group first reported a position in PACB in Q3 2023 and held it in 3 quarters. The position peaked at $53K in Q4 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • KBC Group reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • KBC Group sold 9,997 Pacific Biosciences shares in Q2 2024, an estimated $37K.
  • KBC Group first reported a position in Pacific Biosciences in Q3 2023 and held it in 3 quarters.
  • KBC Group's Pacific Biosciences position peaked at $53K in Q4 2023.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on KBC Group's 13F filing for Q2 2024, filed 17 Jul 2024.